Tilray Medical Launches Redecan Cannabis Brand in Australia
Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), has launched Redecan EU-GMP certified medical cannabis products in Australia. This expansion adds to Tilray's existing medical cannabis portfolio, which includes Tilray and Broken Coast offerings. The launch introduces two new products: Redecan PC THC28 Purple Churro and Redecan SA THC28 Space Age Cake, both available in 15g quantities.
Tilray continues to be a leading provider of EU-GMP certified medical cannabis globally, operating in over 20 countries. The company supports medical trials studying the efficacy of medical cannabis for various conditions, including fibromyalgia, epilepsy, cancer-related symptoms, HIV, and post-traumatic stress disorder.
Tilray Medical, una divisione di Tilray Brands, Inc. (NASDAQ: TLRY e TSX: TLRY), ha lanciato prodotti di cannabis medica certificati EU-GMP in Australia. Questa espansione si aggiunge al portfolio esistente di cannabis medica di Tilray, che include le offerte di Tilray e Broken Coast. Il lancio introduce due nuovi prodotti: Redecan PC THC28 Purple Churro e Redecan SA THC28 Space Age Cake, entrambi disponibili in quantità di 15 g.
Tilray continua a essere un fornitore leader di cannabis medica certificata EU-GMP a livello globale, operando in oltre 20 paesi. L'azienda sostiene studi clinici che esaminano l'efficacia della cannabis medica per varie condizioni, tra cui fibromialgia, epilessia, sintomi correlati al cancro, HIV e disturbo da stress post-traumatico.
Tilray Medical, una división de Tilray Brands, Inc. (NASDAQ: TLRY y TSX: TLRY), ha lanzado productos de cannabis medicinal certificados por EU-GMP en Australia. Esta expansión se suma al portafolio existente de cannabis medicinal de Tilray, que incluye las ofertas de Tilray y Broken Coast. El lanzamiento presenta dos nuevos productos: Redecan PC THC28 Purple Churro y Redecan SA THC28 Space Age Cake, ambos disponibles en cantidades de 15 g.
Tilray sigue siendo un proveedor líder de cannabis medicinal certificado por EU-GMP a nivel mundial, operando en más de 20 países. La empresa apoya ensayos clínicos que estudian la eficacia de la cannabis medicinal para diversas condiciones, incluyendo fibromialgia, epilepsia, síntomas relacionados con el cáncer, VIH y trastorno de estrés post-traumático.
틸레이 메디컬(Tilray Medical)은 틸레이 브랜즈(Tilray Brands, Inc.)의 한 부서(NASDAQ: TLRY 및 TSX: TLRY)로서, 호주에서 EU-GMP 인증을 받은 의료용 대마초 제품을 출시했습니다. 이번 확장은 틸레이의 기존 의료용 대마초 포트폴리오에 추가되며, 여기에는 틸레이와 브로큰 코스트(Broken Coast)의 제품이 포함됩니다. 이번 출시에서는 두 가지 새로운 제품, 레드컨 PC THC28 퍼플 츄로(Redecan PC THC28 Purple Churro)와 레드컨 SA THC28 스페이스 에이지 케이크(Redecan SA THC28 Space Age Cake)가 15g 용량으로 출시됩니다.
틸레이는 전 세계 20개국 이상에서 운영하는 EU-GMP 인증 의료용 대마초의 선도적인 공급업체로 자리 잡고 있습니다. 이 회사는 섬유근육통, 간질, 암 관련 증상, HIV 및 외상 후 스트레스 장애와 같은 다양한 질환에 대한 의료용 대마초의 효능을 연구하는 임상 시험을 지원합니다.
Tilray Medical, une division de Tilray Brands, Inc. (NASDAQ: TLRY et TSX: TLRY), a lancé des produits de cannabis médicinal certifiés EU-GMP en Australie. Cette expansion vient s'ajouter au portefeuille existant de cannabis médicinal de Tilray, qui comprend les offres de Tilray et de Broken Coast. Le lancement introduit deux nouveaux produits : Redecan PC THC28 Purple Churro et Redecan SA THC28 Space Age Cake, tous deux disponibles en quantités de 15 g.
Tilray continue d'être un fournisseur leader de cannabis médicinal certifié EU-GMP à l'échelle mondiale, opérant dans plus de 20 pays. L'entreprise soutient des essais médicaux étudiant l'efficacité du cannabis médicinal pour diverses conditions, y compris la fibromyalgie, l'épilepsie, les symptômes liés au cancer, le VIH et le trouble de stress post-traumatique.
Tilray Medical, eine Abteilung von Tilray Brands, Inc. (NASDAQ: TLRY und TSX: TLRY), hat EU-GMP-zertifizierte medizinische Cannabisprodukte in Australien eingeführt. Diese Expansion ergänzt das bestehende medizinische Cannabisportfolio von Tilray, das die Angebote von Tilray und Broken Coast umfasst. Der Launch führt zwei neue Produkte ein: Redecan PC THC28 Purple Churro und Redecan SA THC28 Space Age Cake, beide erhältlich in 15 g Mengen.
Tilray bleibt ein führender Anbieter von EU-GMP-zertifiziertem medizinischen Cannabis weltweit und ist in über 20 Ländern tätig. Das Unternehmen unterstützt medizinische Studien zur Wirksamkeit von medizinischem Cannabis bei verschiedenen Erkrankungen, darunter Fibromyalgie, Epilepsie, krebsspezifische Symptome, HIV und posttraumatische Belastungsstörung.
- Expansion of product portfolio with the launch of Redecan brand in Australia
- Introduction of two new EU-GMP certified medical cannabis products
- Strengthening of Tilray's position as a leading global provider of medical cannabis
- Ongoing support for medical trials studying cannabis efficacy for various conditions
- None.
The launch of Redecan in Australia marks a strategic expansion for Tilray Medical, potentially boosting its market share in the growing Australian medical cannabis sector. This move diversifies Tilray's product portfolio in the region, which could lead to increased revenue streams.
However, the impact on Tilray's overall financial performance may be in the short term. Australia's medical cannabis market, while growing, is still relatively small compared to Tilray's primary markets. The true value of this expansion lies in its long-term potential as Australia's regulatory environment continues to evolve.
Investors should monitor patient adoption rates and regulatory developments in Australia to gauge the success of this launch. While promising, it's important to view this as part of Tilray's broader international strategy rather than a standalone game-changer.
Tilray's EU-GMP certification for Redecan products is a significant competitive advantage in the Australian market. This certification ensures high-quality standards, potentially leading to greater acceptance among healthcare practitioners and patients.
The introduction of two high-THC strains (Purple Churro and Space Age Cake) suggests Tilray is targeting patients with conditions requiring potent pain relief or strong appetite stimulation. This could position Tilray well in treating chronic pain, cancer-related symptoms and other severe conditions.
Tilray's involvement in various medical trials globally adds credibility to its products and may lead to expanded indications for use in the future. This research-driven approach could translate into a stronger market position and potentially higher prescription rates in the long run.
EU-GMP Certified Redecan Cannabis Now Available in Australia with Medical Prescription
NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray Brands") (NASDAQ: TLRY and TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, today announced the launch of Redecan EU-GMP certified medical cannabis products in Australia.
Denise Faltischek, Chief Strategy Officer and Head of International, Tilray Brands, said, “The launch of Redecan, a premium cannabis brand, in Australia is another significant milestone for Tilray Medical, as we relentlessly pursue our vision of making high-quality medical cannabis products accessible to patients worldwide. The launch of Redecan further expands our medical cannabis portfolios alongside our current Tilray and Broken Coast offerings, as we continue our mission of empowering patients and healthcare practitioners to find the optimal therapeutic solutions.”
Jonathan Trodden, Director, Tilray Medical Australia, adds: “We are proud to launch Redecan in Australia and further strengthen our ongoing commitment to providing patients with a consistent, accessible supply of premium quality medical cannabis to choose from.”
The following Redecan products are now available for medical cannabis patients in Australia:
- Redecan PC THC28 Purple Churro – 15g
- Redecan SA THC28 Space Age Cake – 15g
Tilray continues to be one of the leading providers of EU-GMP certified medical cannabis to patients, physicians, pharmacies, hospitals, governments, and researchers across the globe, and today offers a comprehensive portfolio of THC and CBD products in over 20 countries. In furtherance of its mission, Tilray has supported medical trials globally studying the efficacy of medical cannabis as a treatment for indications including fibromyalgia, pediatric epilepsy, refractory pediatric epilepsy, cancer-induced nausea and vomiting, HIV, essential tremor, breast cancer disorders, post-traumatic stress disorder, and alcohol use disorders.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios and Navcora. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first EU-GMP certified cannabis production facilities in Europe, specifically in Portugal and Germany simultaneously. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments in 20 countries and across five continents.
For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
For further information, please contact:
Media: news@tilray.com
Investors: investors@tilray.com
FAQ
What new medical cannabis products has Tilray (TLRY) launched in Australia?
How many countries does Tilray (TLRY) currently operate in for medical cannabis?
What medical conditions is Tilray (TLRY) supporting research for with cannabis treatments?
When did Tilray (TLRY) announce the launch of Redecan cannabis brand in Australia?
